BSBushra Shal

Bushra Shal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bushra Shal has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Abdul Aziz

    Department of Biochemistry, Dr G D Pol Foundation YMT Dental College and Hospital, Kharghar, Navi Mumbai, India

    1 shared publication
  • Adnan Khan

    Institute of Chemical Sciences, University of Peshawar, Peshawar, Pakistan

    1 shared publication
  • Ashraf Ullah Khan

    Department of Pharmacy, Faculty of Pharmaceutical Sciences, Abasyn University, Peshawar 25120, Pakistan

    1 shared publication
  • Carlos Perez

    Department of Neurology (B.S., M.G., C.P., L.S., H.D., H.A., J.M.C., H.C., S.M., Yi Yang), University of New Mexico Health Science Center, Albuquerque

    1 shared publication
  • Halima Akter

    Department of Neurology (B.S., M.G., C.P., L.S., H.D., H.A., J.M.C., H.C., S.M., Yi Yang), University of New Mexico Health Science Center, Albuquerque

    1 shared publication
  • Haojie Chen

    Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, NM 87131

    1 shared publication

Latest Publications

  • SEW2871 Attenuates Blood-Brain Barrier Damage and Neuropathological Outcomes Related to Cerebral Small Vessel Disease

    by Bushra Shal, Michael Griego, Yirong Yang, Carlos Perez, Laurel Sillerud, Haoran Deng, Halima Akter, Joanna McChriston, Haojie Chen, Sean Maez, et al.

    BACKGROUND: Blood-brain barrier (BBB) dysfunction contributes to the pathogenesis of cerebral small vessel disease. This study assessed SEW2871, a selective agonist of sphingosine-1-phosphate receptor 1, as a potential novel therapy for small vessel disease by targeting BBB damage using a rat model of small vessel disease. METHODS: Twelve-week male and female spontaneously hypertensive rat stroke-prones were subjected to unilateral carotid artery occlusion (UCAO) and Japanese permissive diet (JPD). Three doses of SEW2871 (0.5, 1.0, and 5.0 mg/kg, delivered every other day up to 5 weeks) were tested. Dynamic body weight, oxygen saturation, and SEW2871 plasma concentration were evaluated. BBB permeability, white matter lesions and gray matter lesions, and cerebral blood flow (CBF) were assessed with preclinical magnetic resonance imaging at 2 and 5 weeks after UCAO/JPD onset. Cognitive outcomes were evaluated using Morris Water Maze during week 5 of UCAO/JPD. RESULTS: We found that SEW2871 delayed the occurrence of UCAO/JPD-induced chronic hypoxic hypoperfusion in the spontaneously hypertensive rat stroke-prones. Magnetic resonance imaging showed increased BBB permeability, white matter lesions and gray matter lesions, and decreased CBF at 2 and 5 weeks after UCAO/JPD onset. T 2 -weighted and fractional anisotropy magnetic resonance imaging showed that all doses of SEW2871 demonstrated a protective effect on white matter lesions and gray matter lesions with the most significant improvements in the 1.0 mg/kg group. Dynamic contrast-enhanced magnetic resonance imaging and arterial spin labeling maps showed significantly reduced BBB leakage and improved CBF in 0.5 and 1.0 mg/kg groups. Immunohistochemical analysis for serum IgG extravasation and microglia/macrophage activation in rat brains verified the protective effects of SEW2871 on BBB leakage and neuroinflammation. Morris Water Maze test revealed a significant improvement in spatial memory in 0.5 and 1.0 mg/kg groups compared with the vehicle animals. CONCLUSIONS: Long-term treatment with SEW2871 mitigated BBB leakage and brain injury, improved CBF and cognitive impairment in the spontaneously hypertensive rat stroke-prone model of small vessel disease. SEW2871 is effective at all doses, while 1.0 mg/kg dose demonstrated exceptional protection against the neuropathological cascades associated with small vessel disease.


  • Retracted

    RETRACTED ARTICLE: Ameliorative effect of two structurally divergent hydrazide derivatives against DSS-induced colitis by targeting Nrf2 and NF-κB signaling in mice

    by Ashrafullah Khan, Adnan Khan, Bushra Shal, Abdul Aziz, Sajjad Ahmad, Muhammad Usman Amin, Muhammad Naeem Ahmed, Zia- Ur- Rehman, Salman Khan

    The environmental factors and genetic vulnerability trigger the inflammatory bowel diseases (IBDs) such as ulcerative colitis and Crohn’s disease. Furthermore, the oxidative stress and inflammatory cytokines have been implicated in the aggravation of the IBDs. The aim of the present study was to investigate the effect of N-(benzylidene)-2-((2-hydroxynaphthalen-1-yl)diazenyl)benzohydrazides (NCHDH and NTHDH) compounds against the DSS-induced colitis in mice. The colitis was induced by 5% dextran sulfate sodium (DSS) dissolved in normal saline for 5 days. The effect of the NCHDH and NTHDH on the behavioral, biochemical, histological, and immunohistological parameters was assessed. The NCHDH and NTHDH treatment improved the behavioral parameters such as food intake, disease activity index, and diarrhea score significantly compared to DSS control. The NCHDH and NTHDH treatments significantly increased the antioxidant enzymes, whereas oxidative stress markers were markedly reduced. Similarly, the NCHDH and NTHDH treatments significantly suppressed the activity of nitric oxide (NO), myeloperoxidase (MPO), and eosinophil peroxidase (EPO). The histological studies showed a significant reduction in inflammation, immune cell infiltration, and fibrosis in the NCHDH- and NTHDH-treated groups. The immunohistochemical results demonstrated that NCHDH and NTHDH treatments markedly increase the expression level of Nrf2, HO-1 (hemeoxygenase-1), TRX (thioredoxin reductase), and IκB compared to the DSS-induced group. In the same way, the NCHDH and NTHDH significantly reduced the NF-κB and COX-2 (cyclooxygenase-2) expression levels. The NCHDH and NTHDH treatment significantly improved the symptoms associated with colitis via inducing antioxidants and attenuating oxidative stress markers.